Pictured left to right: Jennie Lynch (Enterprise Ireland), Ronan McClafferty (Solvotrin Therapeutics), Pat O’Flynn (Solvotrin Therapeutics), Minister for Health, Jennifer Carroll MacNeill, Gary Powers (Ortho Molecular Products), Nate Freeman (Ortho Molecular Products) and Anni Wang (Enterprise Ireland).
Union League Club of Chicago, March 14, 2025 – Solvotrin Therapeutics, a leading Irish healthcare development company, is pleased to announce an exclusive agreement with Ortho Molecular Products for the distribution of Active Iron in the U.S. practitioner channel. Active Iron is an innovative range of oral iron products that are patent protected, and backed by two clinical studies. The partnership will introduce Active Iron to healthcare providers, further strengthening both companies’ commitment to delivering innovative and effective nutritional solutions. The announcement was made at the Irish American Partnership Breakfast attended by Enterprise Ireland and distinguished guests including the Minister for Health, Jennifer Caroll MacNeill.
For more than 35 years, Ortho Molecular Products has been a trusted partner to healthcare providers, offering efficacious nutritional solutions that clinicians depend on to get patients better faster. This collaboration aligns with Ortho Molecular Products’ vision to transform healthcare through physician-directed clinical nutrition to achieve better patient outcomes.
“We are thrilled to partner with Ortho Molecular Products to introduce Active Iron to the U.S. practitioner channel,” said Ronan McClafferty, Chief Operating Officer at Solvotrin Therapeutics. “This partnership is built on shared values and a mission to improve health outcomes through innovative solutions. We are confident that Ortho Molecular Products’ deep expertise and strong relationships with healthcare providers will ensure Active Iron makes a meaningful impact in the U.S. market.”
Gary Powers, Founder and Chief Executive Officer at Ortho Molecular Products, echoed this enthusiasm, “At Ortho Molecular Products, we are committed to providing healthcare professionals with clinically proven, efficacious nutritional solutions. Active Iron is an outstanding addition to our portfolio, and we are excited to bring this innovative iron supplement to the practitioner channel. With its unique formulation and strong clinical backing, we believe it will deliver significant benefits to those patients who need iron support the most.”
Pictured left to right: Gary Powers (Ortho Molecular Products), Pat O’Flynn (Solvotrin Therapeutics) and Ronan McClafferty (Solvotrin Therapeutics).
The partnership aims to achieve $15 million in retail sales value (RSV) within the first three years, highlighting the strong market potential for Active Iron in the practitioner space. With a shared vision of delivering science-driven solutions, this collaboration marks a significant milestone in expanding access to effective iron supplementation through trusted healthcare providers.
About Solvotrin Therapeutics
Solvotrin Therapeutics is an Irish healthcare development company focused on optimizing established therapies through innovation and patent protection. The company has successfully commercialised the Active Iron platform technology, featuring a range of innovative oral iron products available in 15 markets worldwide.
About Ortho Molecular Products
For more than 35 years, Ortho Molecular Products has partnered exclusively with healthcare providers to deliver efficacious nutritional solutions. The most trusted voices in healthcare rely on Ortho Molecular Products to help patients achieve better health outcomes, faster. Through unwavering commitment to quality and innovation, Ortho Molecular Products continues to be a leader in the practitioner channel.